Key Takeaways VTRS reported four regulatory achievements, including FDA approval of a generic Sandostatin LAR injectable.VTRS' low-dose estrogen weekly patch NDA was accepted, with an FDA action date set for July 30, 2026.VTRS also cleared an IND for MR-146 gene therapy and gained Japan NDA acceptance for pitolisant in OSAS.Viatris Inc. (VTRS) recently announced four regulatory achievements across multiple stages of its pipeline.These achievements outline the company’s R&D progress in 2025. VTRS will contin ...